611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
Long COVID Can Last a Year; Many Sufferers Quit JobsWould You Like Phthalates With That? Fast Food Contains Industrial Chemicals: ReportMany Blood Cancer Patients Get Little Protection From COVID VaccineMerck Allows Poor Nations to Make COVID-19 PillHow Folks Are Coping With Post-COVID Loss of Smell, TasteRoutine Ventilation of Surgical Patients Won't Raise COVID Transmission RiskImmunocompromised May Need Fourth COVID Shot: CDCLiver Transplants Soar as Some Americans Drink Their Way Through the PandemicFDA Advisors Approve Emergency Use of Pfizer COVID Vaccine in Kids 5 to 11COVID Vaccination Can Be Safe Even in People With Severe AllergiesTargeted High-Dose Radiation Helps Fight Advanced Lung CancerTrader Joe's Salami Snacks Tied to 20 Salmonella Cases in 8 StatesWhite House Takes More Steps to Boost Supply of Rapid at-Home COVID TestsBiden Administration Announces Details of Vaccination Requirements for Foreign TravelersAHA News: Never Heard of Sepsis? It's Common, Dangerous and a Threat to Your HeartModerna Says Its COVID Vaccine Works Well in Children Aged 6 to 11COVID Vaccination Does Not Raise Odds of Miscarriage: StudyVaccinated People Less Likely to Die of Any Cause in Months After Shots: CDCRecovering COVID Patients Often Face Long-Term 'Brain Fog'COVID Pandemic May Have Driven a Flu Strain Into ExtinctionThe No. 1 Cause of Halloween Injuries: Carving the PumpkinPfizer Vaccine Prevents 91% of Symptomatic COVID in Young Children: FDAPfizer Says Lower Dose of Its COVID Vaccine Protects Younger ChildrenDeadly Liver Disease Tied to Obesity Is on the RiseCDC Signs Off on Moderna, J&J Boosters, Backs Mix n' Match ShotsMoving Monoclonal Antibody Treatments for COVID From Hospital to HomeConfusion, Seizures: People Hospitalized After Taking Veterinary Drug for COVIDMandates, Not Recommendations, Work Best to Get Folks Vaccinated: StudyPfizer Vaccine Booster Restores Nearly Full Protection, Company SaysTen Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune DiseaseSex of Fetus May Matter When COVID Strikes in PregnancyVaccines Cut Odds for Death From COVID Delta Variant by 90%U.S. Has Shared 200 Million Shots With Other CountriesSalmonella Outbreak in 37 States Linked to Imported OnionsFDA Approves Moderna, J&J Booster Shots, Backs Mix n' Match VaccinesWhite House Announces COVID Vaccination Plan for Young KidsEven With Mild COVID, Obesity May Mean Worse SymptomsNew Device Might Spot 'Lazy Eye' in Kids EarlierA High-Tech Pointer to Pollutants That Trigger Asthma in KidsFlu Cases Already Up 23% This Season: WalgreensDoctors Report That Kidney Grown in Pig Worked in a HumanHeartburn Meds Might Be Good for Your GumsOne Big Factor for Survival After Spinal Cord Injury: ResilienceDying Young From Heart Disease: Where You Live in the U.S. MattersFDA Expected to Allow Mix n' Match COVID VaccinesPowell's COVID Death Despite Vaccination Shows Danger to Those With Weakened Immune SystemsAHA News: Your Next Doctor's Prescription Might Be to Spend Time in NatureOut-of-Pocket Medical Bills for COVID-19 May Average $3,800 in 2021: StudyLegionnaires' Disease Outbreak Hits Long Island, N.Y.State Lotteries Didn't Help Boost Vaccination Rates
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Pfizer, Moderna Vaccines Still Offer Good Protection Against Severe COVID: Study

HealthDay News
by By Ernie Mundell HealthDay Reporter
Updated: Sep 17th 2021

new article illustration

FRIDAY, Sept. 17, 2021 (HealthDay News) -- With a special advisory panel to the U.S. Food and Drug Administration meeting Friday to decide on the need for COVID vaccine booster shots, new data shows Pfizer-BioNTech and Moderna vaccines maintaining strong levels of protection against severe illness.

The data tracked the cases of nearly 3,700 American adults cared for at 21 hospitals across the nation from March 11 to Aug. 15, 2021 -- a time span that dovetails with the emergence and dominance of the highly contagious Delta variant.

Nearly half (about 46%) were admitted with COVID-like illness and later tested positive for the new coronavirus; the rest did not have COVID.

Comparing the patients' vaccination histories, a team led by Dr. Wesley Self of Vanderbilt University Medical Center in Nashville, Tenn., wrote that "vaccine effectiveness against COVID-19 hospitalizations was higher for the Moderna vaccine" at 93%. Effectiveness of the Pfizer vaccine came in slightly lower at 88%.

Both of the two-dose mRNA-based regimens beat the effectiveness of the one-dose Johnson & Johnson vaccine, which maintained 71% effectiveness in warding off a case of COVID-19 so severe that it would require hospitalization.

There was some sobering news for folks who got the Pfizer shot: "Protection for the Pfizer-BioNTech vaccine declined 4 months after vaccination," Self's group noted, although it still remained high.

No such decline in effectiveness was seen for people who got the Moderna shots.

Another arm of the study looked at levels of antibodies to the new coronavirus in 100 healthy volunteers. Samples were taken two to six weeks after they had gotten fully vaccinated with any of the three vaccines.

The result: Antibody levels "were significantly lower in persons vaccinated with the Janssen [J&J] vaccine than the Moderna or Pfizer-BioNTech vaccines," the researchers reported.

The Moderna vaccine also produced higher "antibody levels than did the Pfizer-BioNTech vaccine," the researchers said.

They suspect that could be because of higher levels of protective mRNA in the Moderna vaccine than in the Pfizer shot, or because people who got the Moderna shot typically received their second dose slightly later than people who received the Pfizer regimen (four weeks versus three weeks, respectively).

However, according to the research team, the takeaway is clear: "All FDA-approved or [emergency]-authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization."

Self's team stressed that the study had some limitations.

First, assessment of the J&J vaccine is hampered because relatively fewer Americans received that shot compared to the many tens of millions who received the two-dose vaccines.

And although the study occurred during the time that the Delta variant became dominant in the United States, researchers did not examine each vaccine's effectiveness against it specifically.

The findings were published Sept. 17 in Morbidity and Mortality Weekly Report, a journal of the U.S. Centers for Disease Control and Prevention.

The new data will surely be part of deliberations by an FDA advisory committee convened Friday to decide whether third "booster" shots are necessary for the average American. (Third shots have already been approved for people with compromised immune systems).

While today's new data suggest that vaccine-induced immunity remains high against severe COVID, data from Israel suggests boosters could be helpful. Israel began offering boosters to its citizens this summer.

In the Israeli study, published Sept. 15 in the New England Journal of Medicine, more than 1 million people aged 60 and older got a third dose. The data show they were much less likely to become infected soon after with the contagious Delta variant, according to the Associated Press, achieving what Pfizer called "roughly 95% effectiveness." It is not known how long that protection will last.

However, FDA reviewers have suggested they would primarily focus not on the Israeli data but on how vaccines have worked among Americans, which they said "may most accurately represent vaccine effectiveness in the U.S. population."

Pfizer, meanwhile, has indicated that its vaccine is protecting against severe disease in the United States, but immunity against milder infections wanes around six to eight months after the second dose.

Pfizer gave third doses to 306 individuals and found their antibodies were three times higher than after earlier doses, the AP reported. The company said the antibodies appeared strong enough to be effective for the Delta variant.

The need for booster shots has become a contentious issue in recent weeks, after President Joe Biden announced a booster campaign that was slated to begin Sept. 20. Soon after that announcement two top FDA vaccine regulators joined with international scientists to release a report contending that boosters are not needed for healthy individuals, because the vaccines continue to offer strong protection from severe disease.

Although the FDA is not bound to follow the advice of its advisory committees, it typically does so.

More information

Find out more about the effectiveness of COVID-19 vaccines at the U.S. Centers for Disease Control and Prevention.

SOURCES: U.S. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, Sept. 17, 2021; Associated Press, Sept. 16, 2021